Durham, United States
Aceragen is a rare disease biopharmaceutical company founded in 2021 with a clear mission to address rare, orphan diseases with no available treatment. Their slogan, "Aceragen is a rare disease company striving to restore a better life for patients and families," reflects their commitment to improving the lives of patients and families affected by neglected rare diseases.
Their focus on Biotechnology, Healthcare, and Pharmaceutical industries positions them as a significant player in the healthcare sector. The company's headquarters is located in the United States.
Aceragen's dedication to developing novel therapies for rare diseases is evident in their latest milestone. In May 2021, they secured a substantial $35.00M Private Equity Round investment led by Novaquest Capital Management. This investment signifies the confidence of investors in Aceragen's potential to make a meaningful impact in the rare disease space.
Aceragen's vision to provide rare-disease patients with compelling new therapeutic options aligns with their strategic approach of engaging in community awareness, regulatory outreach, and delivering novel treatments. Through their collective conviction, Aceragen aims to bring a much-needed spotlight to rare and orphan diseases, ultimately changing the world for the better.
